Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-03-28FDA Approved: LACOSAMIDE ORAL SOLUTION — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application to authorize lacosamide oral solution from Ascend Laboratories, expanding the product's dosage f…
-
FDA approval · 2023-03-24FDA Approved: PREGABALIN — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for pregabalin from Solco Healthcare US, LLC under ANDA207883. The drug is indicated for neuropathic…
-
FDA approval · 2023-03-24FDA Approved: PREGABALIN — Supplemental Application (Tris Pharma Inc)
FDA approved a supplemental application for pregabalin submitted by Tris Pharma Inc.
-
FDA approval · 2023-03-14FDA Approved: OXCARBAZEPINE — Supplemental Application (EPIC PHARMA, LLC)
The FDA approved a supplemental application for oxcarbazepine filed by Epic Pharma, LLC.
-
FDA approval · 2023-02-09FDA Approved: LACOSAMIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original generic application for lacosamide by Novadoz Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-02-06FDA Approved: LACOSAMIDE — Original Application (Kanchan Healthcare Inc)
FDA approved a generic lacosamide product under ANDA216461, produced by Kanchan Healthcare Inc. This adds a generic option for lacosamide in…
-
FDA approval · 2023-01-18FDA Approved: LACOSAMIDE — Supplemental Application (XLCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for lacosamide submitted by XLCare Pharmaceuticals Inc., updating the product labeling under the…
-
FDA approval · 2023-01-06FDA Approved: BRIVARACETAM — Original Application (Aurobindo Pharma Limited)
FDA approved a generic version of brivaracetam from Aurobindo Pharma Limited under an Original Application (ANDA 214848).
-
FDA approval · 2023-01-05FDA Approved: LACOSAMIDE — Original Application (Aurobindo Pharma Limited)
FDA granted approval for lacosamide as an Original Application for Aurobindo Pharma Limited, enabling a generic lacosamide product.
-
FDA approval · 2022-11-30FDA Approved: OXCARBAZEPINE — Original Application (EPIC PHARMA, LLC)
FDA approved a generic oxcarbazepine product from Epic Pharma through an Original Application (ANDA).
-
FDA approval · 2022-11-04FDA Approved: OXCARBAZEPINE — Original Application (Bionpharma Inc.)
FDA approved the generic oxcarbazepine under an Original Application for Bionpharma Inc.
-
FDA approval · 2022-10-03FDA Approved: BRIVARACETAM — Original Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a generic version of brivaracetam (BRIVARACETAM) from Zydus Pharmaceuticals USA Inc. under Original Application ANDA214501.
-
FDA approval · 2022-09-30FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Vimpat (lacosamide) filed by UCB, Inc., signaling an FDA-approved expansion or modification to t…
-
FDA approval · 2022-09-30FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., resulting in a labeling update for the drug.
-
FDA approval · 2022-09-19FDA Approved: LACOSAMIDE — Original Application (Gland Pharma Limited)
FDA approved an original application for lacosamide from Gland Pharma Limited to market a generic lacosamide product. The approval covers it…
-
FDA approval · 2022-09-14FDA Approved: LACOSAMIDE — Original Application (XLCare Pharmaceuticals Inc.)
The FDA approves XLCare Pharmaceuticals' original ANDA for lacosamide, making a generic lacosamide available in the market.
-
FDA approval · 2022-09-01FDA Approved: PREGABALIN — Original Application (Solco Healthcare US, LLC)
FDA approved Solco Healthcare US, LLC's original ANDA for pregabalin (generic pregabalin). This marks the approval of a generic version of p…
-
FDA approval · 2022-08-26FDA Approved: LACOSAMIDE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved ANI Pharmaceuticals' Original Abbreviated New Drug Application for lacosamide, authorizing the marketing of a generic lacosamid…
-
FDA label_change · 2022-08-04FDA Approved: OXCARBAZEPINE — Supplemental Application (Advagen Pharma Limited)
The FDA issued a supplemental approval for oxcarbazepine by Advagen Pharma Limited, resulting in changes to the product's labeling.
-
FDA approval · 2022-07-18FDA Approved: PREGABALIN — Original Application (MARKSANS PHARMA LIMITED)
FDA approved the original ANDA for pregabalin from Marksans Pharma Limited (ANDA216197).
-
FDA approval · 2022-07-15FDA Approved: ZONISADE — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved ZONISADE (zonisamide) via an original NDA for use in epilepsy, including partial-onset seizures.
-
FDA approval · 2022-07-15FDA Approved: LEVETIRACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves Novadoz's original ANDA for Levetiracetam, establishing a generic anti-seizure medication. Indications include epilepsy-related…
-
FDA approval · 2022-06-29FDA Approved: LACOSAMIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved lacosamide via an original generic application (ANDA) for Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2022-06-27FDA Approved: XCOPRI — Supplemental Application (SK Life Science, Inc.)
The FDA approved a supplemental application for XCOPRI (cenobamate) from SK Life Science, expanding its label for seizure indications.
-
FDA approval · 2022-06-09FDA Approved: BRIVARACETAM — Original Application (SolarisPharmaCorporation)
FDA approved an abbreviated new drug application for brivaracetam (generic) by SolarisPharmaCorporation under ANDA214748, enabling a generic…